BR112021024363A2 - Purificação de saponina - Google Patents

Purificação de saponina

Info

Publication number
BR112021024363A2
BR112021024363A2 BR112021024363A BR112021024363A BR112021024363A2 BR 112021024363 A2 BR112021024363 A2 BR 112021024363A2 BR 112021024363 A BR112021024363 A BR 112021024363A BR 112021024363 A BR112021024363 A BR 112021024363A BR 112021024363 A2 BR112021024363 A2 BR 112021024363A2
Authority
BR
Brazil
Prior art keywords
saponin
purification
saponin purification
extracts
absorbance
Prior art date
Application number
BR112021024363A
Other languages
English (en)
Inventor
Berthe Ghislaine De Kesel Carine
Austin Farrenburg Chad
Yeatts Vandenburg Jeb
Kay Sandvick Jeri
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112021024363A2 publication Critical patent/BR112021024363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

purificação de saponina. extratos de saponina contendo pelo menos 88% de pico principal de qs-21 e >3% a 10% de componente 2018 por absorvância de uv em 214 nm, métodos para preparar os referidos extratos, seu uso como adjuvantes de vacina e aspectos relacionados.
BR112021024363A 2019-06-05 2020-06-03 Purificação de saponina BR112021024363A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857490P 2019-06-05 2019-06-05
US202062966170P 2020-01-27 2020-01-27
PCT/EP2020/065366 WO2020245207A1 (en) 2019-06-05 2020-06-03 Saponin purification

Publications (1)

Publication Number Publication Date
BR112021024363A2 true BR112021024363A2 (pt) 2022-03-22

Family

ID=71083599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024363A BR112021024363A2 (pt) 2019-06-05 2020-06-03 Purificação de saponina

Country Status (7)

Country Link
US (1) US20220235095A1 (pt)
EP (1) EP3980044A1 (pt)
JP (1) JP2022535091A (pt)
CN (1) CN114080393A (pt)
BR (1) BR112021024363A2 (pt)
CA (1) CA3142300A1 (pt)
WO (1) WO2020245207A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023223255A1 (en) 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69017769T2 (de) 1989-06-27 1995-07-13 Smithkline Beecham Biolog Verbindungen.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
DK0614465T3 (da) 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
HU221420B1 (en) * 1993-01-22 2002-09-28 Sloan Kettering Inst Cancer Ganglioside-protein conjugate vaccines
EP0699076B1 (en) 1993-05-18 2002-10-30 The Ohio State University Research Foundation Otitis media vaccine
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2748748B1 (fr) 1996-05-17 1998-11-06 Pasteur Institut Identification et clonage d'un antigene mycobacterien correspondant a une hemagglutine de liaison a l'heparine
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
ES2297841T3 (es) * 1996-12-02 2008-05-01 Antigenics Inc. Nuevas composiciones de saponina y usos de las mismas.
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
ATE380867T1 (de) 1997-06-03 2007-12-15 Sanofi Pasteur Ltd Lactoferrinrezeptorgen von moraxella
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
FR2832410B1 (fr) 2001-11-19 2004-04-02 Pasteur Institut Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
ATE529123T1 (de) * 2002-04-15 2011-11-15 Oncothyreon Inc Synthetische glykolipopeptide als impfstoffe
DE602004026218D1 (de) 2003-12-23 2010-05-06 Nationwide Childrens Hospital Pili von haemophilus influenzae typ iv
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
SI2486938T1 (sl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Sestavek cepiva, ki vsebuje sintetični adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AR065523A1 (es) 2007-03-02 2009-06-10 Glaxosmithkline Biolog Sa Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones
BRPI0821532A2 (pt) 2007-12-24 2015-06-16 Id Biomedical Corp Quebec Antígenos de rsv recombinantes
KR20110060891A (ko) 2008-07-25 2011-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 조성물 및 방법
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
ES2602430T3 (es) 2008-07-25 2017-02-21 Glaxosmithkline Biologicals S.A. Polipéptidos, polinucleótidos y composiciones para uso en el tratamiento de tuberculosis latente
US20130018178A1 (en) 2009-06-22 2013-01-17 Px Therapeutics Method for the purification of hbha
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
JP6010463B2 (ja) 2010-01-27 2016-10-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変された結核抗原
EA027920B1 (ru) 2010-12-14 2017-09-29 Глаксосмитклайн Байолоджикалс С.А. Композиция микобактериальных антигенов
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
GB201316463D0 (en) 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10455225B2 (en) 2017-05-12 2019-10-22 Pure Depth Limited Multi-layered display with interstitial layer air filter
BR112020010635A2 (pt) * 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina

Also Published As

Publication number Publication date
JP2022535091A (ja) 2022-08-04
CN114080393A (zh) 2022-02-22
CA3142300A1 (en) 2020-12-10
EP3980044A1 (en) 2022-04-13
US20220235095A1 (en) 2022-07-28
WO2020245207A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
CL2020001440A1 (es) Purificación de saponina
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
NI202000078A (es) Compuestos heteroaril tetracíclicos
BR112017020837A2 (pt) compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
BR112017002970A2 (pt) novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018007664A2 (pt) antagonistas de ep4
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
BR112016016130A2 (pt) Compostos e métodos
BR112017015116A2 (pt) derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BR112021024363A2 (pt) Purificação de saponina
CL2020001439A1 (es) Extracción de saponina
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CL2021000646A1 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.